Bliss GVS Pharma Limited (NSE:BLISSGVS)
India
· Delayed Price · Currency is INR 149.30
+0.87 (0.59%)
Jun 13, 2025, 3:29 PM IST
Bliss GVS Pharma Revenue
In the fiscal year ending March 31, 2025, Bliss GVS Pharma had annual revenue of 8.10B INR with 5.13% growth. Bliss GVS Pharma had revenue of 1.98B in the quarter ending March 31, 2025, a decrease of -0.07%.
Revenue
8.10B
Revenue Growth
+5.13%
P/S Ratio
1.94
Revenue / Employee
9.74M
Employees
831
Market Cap
15.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 8.10B | 394.81M | 5.13% |
| Mar 31, 2024 | 7.70B | 186.57M | 2.48% |
| Mar 31, 2023 | 7.52B | 41.33M | 0.55% |
| Mar 31, 2022 | 7.47B | 1.70B | 29.50% |
| Mar 31, 2021 | 5.77B | -1.12B | -16.26% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |
Bliss GVS Pharma News
- 2 months ago - Bliss GVS Clarifies USFDA ANDA Approval for Mesalamine Suppositories - Business Upturn
- 7 months ago - Bliss GVS Pharma shares surge 4% after company receives GMP Compliance certification for its manufacturing facilities in Palghar - Business Upturn
- 7 months ago - Bliss GVS Pharma receives GMP Compliance certification for manufacturing facilities in Palghar, Maharashtra - Business Upturn